Novel diagnostic and prognostic biomarkers in esophageal cancer

Bibliography

• Vizcaino AP, Moreno V, Lambert R, et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99(6):860-8
   PubMed Web of Science ®Google Scholar
• Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet 2013;381(9864):400-12
   PubMed Web of Science ®Google Scholar
• Bollschweiler E, Wolfgarten E, Gutschow C, et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001;92(3):549-55
   PubMed Web of Science ®Google Scholar
• Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012;23(12):3155-62
   PubMed Web of Science ®Google Scholar
• Freedman ND, Murray LJ, Kamangar F, et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut 2011;60(8):1029-37
   PubMed Web of Science ®Google Scholar
• Hölscher AH, Bollschweiler E, Schröder W, et al. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg 2011;254:802-7
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84
   PubMed Web of Science ®Google Scholar
• Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009;20:231-8
   PubMed Web of Science ®Google Scholar
• Sjöquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12(7):681-92
   PubMed Web of Science ®Google Scholar
• Bollschweiler E, Hölscher AH, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncol 2010;6(1):25-35
   PubMed Web of Science ®Google Scholar
• Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85(4):350-5
   PubMed Web of Science ®Google Scholar
• Quillien V, Raoul JL, Laurent JF, et al. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma. Oncol Rep 1998;5(6):1561-5
   PubMed Web of Science ®Google Scholar
• Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112(1):40-6
   PubMed Web of Science ®Google Scholar
• Mealy K, Feely J, Reid I, et al. Tumour marker detection in oesophageal carcinoma. Eur J Surg Oncol 1996;22(5):505-7
   PubMedGoogle Scholar
• Zhai XH, Yu JK, Lin C, et al. Combining proteomics, serum biomarkers and bioinformatics to discriminate between esophageal squamous cell carcinoma and pre-cancerous lesion. J Zhejiang Univ Sci B 2012;13(12):964-71
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ide H, Eguchi R, et al. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 1998;11(1):35-9
   PubMedGoogle Scholar
• Pectasides D, Mylonakis A, Kostopoulou M, et al. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 1997;20(4):348-53
   PubMed Web of Science ®Google Scholar
• Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer–a survey. Biochim Biophys Acta 2007;1775(1):181-232
   PubMed Web of Science ®Google Scholar
• Tomita H, Ichikawa D, Ikoma D, et al. Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res 2007;27(4C):2737-41
   PubMed Web of Science ®Google Scholar
• Yang B, Jiang J, Du H, et al. Decreased monoamine oxidase (MAO) activity and MAO-A expression as diagnostic indicators of human esophageal cancers. Biomarkers 2009;14(8):624-9
   PubMed Web of Science ®Google Scholar
• Kadri SR, Lao-Sirieix P, O'Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010;341:c4372
   PubMedGoogle Scholar
• Hoffmann AC, Vallböhmer D, Grimminger P, et al. Preoperative survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma. Pharmacogenomics 2010;11(3):341-7
   PubMed Web of Science ®Google Scholar
• Hoffmann AC, Warnecke-Eberz U, Luebke T, et al. Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers. J Surg Oncol 2007;95(1):51-4
   PubMed Web of Science ®Google Scholar
• Warnecke-Eberz U, Hokita S, Xi H, et al. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 2005;13(6):1241-6
   PubMed Web of Science ®Google Scholar
• Altznauer F, Martinelli S, Yousefi S, et al. Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med 2004;199(10):1343-54
   PubMed Web of Science ®Google Scholar
• Song J, So T, Cheng M, et al. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 2005;22(5):621-31
   PubMed Web of Science ®Google Scholar
• Bahl K, Saraya A, Sharma R. Increased levels of circulating and tissue mRNAs of Oct-4, Sox-2, Bmi-1 and Nanog is escc patients: potential tool for minimally invasive cancer diagnosis. Biomark Insights 2012;7:27-37
   PubMedGoogle Scholar
• Ghorbian S, Ardekani AM. Non-invasive detection of esophageal cancer using genetic changes in circulating cell-free DNA. Avicenna J Med Biotechnol 2012;4(1):3-13
   Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5(7):522-31
   PubMed Web of Science ®Google Scholar
• Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 2012;143(1):35-47; e2
   PubMed Web of Science ®Google Scholar
• Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008;135(2):255-60
   PubMed Web of Science ®Google Scholar
• Guo Y, Chen Z, Zhang L, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008;68(1):26-33
   PubMed Web of Science ®Google Scholar
• Kano M, Seki N, Kikkawa N, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010;127(12):2804-14
   PubMed Web of Science ®Google Scholar
• Mathé EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009;15(19):6192-200
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang H, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010;251(6):1056-63
   PubMed Web of Science ®Google Scholar
• Fassan M, Volinia S, Palatini J, et al. MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer 2011;129(7):1661-70
   PubMed Web of Science ®Google Scholar
• Yang H, Gu J, Wang KK, et al. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 2009;15(18):5744-52
   PubMed Web of Science ®Google Scholar
• Wijnhoven BP, Hussey DJ, Watson DI, et al. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg 2010;97(6):853-61
   PubMed Web of Science ®Google Scholar
• Komatsu S, Ichikawa D, Takeshita H, et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 2011;105(1):104-11
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang C, Chen X, et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 2010;56(12):1871-9
   PubMed Web of Science ®Google Scholar
• Zhang T, Wang Q, Zhao D, et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond) 2011;121(10):437-47
   PubMed Web of Science ®Google Scholar
• Takeshita N, Hoshino I, Mori M, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer 2013;108(3):644-52
   PubMed Web of Science ®Google Scholar
• Liu R, Liao J, Yang M, et al. Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans. J Toxicol Environ Health A 2012;75(18):1154-62
   PubMed Web of Science ®Google Scholar
• Revilla-Nuin B, Parrilla P, Lozano JJ, et al. Predictive value of MicroRNAs in the progression of barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann Surg 2013;257(5):886-93
   PubMed Web of Science ®Google Scholar
• Leidner RS, Ravi L, Leahy P, et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer 2012;51(5):473-9
   PubMed Web of Science ®Google Scholar
• Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59(1):67-70
   PubMed Web of Science ®Google Scholar
• Jin Z, Olaru A, Yang J, et al. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res 2007;13(21):6293-300
   PubMed Web of Science ®Google Scholar
• Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92(22):1805-11
   PubMed Web of Science ®Google Scholar
• Hibi K, Taguchi M, Nakayama H, et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001;7(10):3135-8
   PubMed Web of Science ®Google Scholar
• Liu JB, Qiang FL, Dong J, et al. Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma. World J Gastroenterol 2011;17(44):4917-21
   PubMed Web of Science ®Google Scholar
• Wang CC, Mao WM, Ling ZQ. DNA methylation status of RARβ2 and p16(INK4α) in peripheral blood and tumor tissue in patients with esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi 2012;34(6):441-5
   PubMedGoogle Scholar
• Okamoto M, Hirata S, Sato S, et al. Frequent increased gene copy number and high protein expression of tRNA (cytosine-5-)-methyltransferase (NSUN2) in human cancers. DNA Cell Biol 2012;31(5):660-71
   PubMed Web of Science ®Google Scholar
• Pawar H, Kashyap MK, Sahasrabuddhe NA, et al. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther 2011;12(6):510-22
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang K, Zhang J, et al. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res 2011;10(6):2863-72
   PubMed Web of Science ®Google Scholar
• Shi ST, Yang GY, Wang LD, et al. Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenesis 1999;20(4):591-7
   PubMed Web of Science ®Google Scholar
• Abbaszadegan MR, Raziee HR, Ghafarzadegan K, et al. Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma. Int J Gastrointest Cancer 2005;36(1):47-54
   PubMedGoogle Scholar
• Langer R, Rauser S, Feith M, et al. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod Pathol 2011;24(7):908-16
   PubMed Web of Science ®Google Scholar
• Wang L, Chen J, Chen L, et al. 1H-NMR based metabonomic profiling of human esophageal cancer tissue. Mol Cancer 2013;12:25
   PubMedGoogle Scholar
• Liu R, Peng Y, Li X, et al. dentification of Plasma Metabolomic Profiling for Diagnosis of Esophageal Squamous-Cell Carcinoma Using an UPLC/TOF/MS Platform. Int J Mol Sci 2013;14(5):8899-911
   PubMed Web of Science ®Google Scholar
• Davis VW, Schiller DE, Eurich D, et al. Urinary metabolomic signature of esophageal cancer and Barrett's esophagus. World J Surg Oncol 2012;10:271
   PubMedGoogle Scholar
• Morodomi T, Isomoto H, Shirouzu K, et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989;63(3):539-43
   PubMed Web of Science ®Google Scholar
• Teramoto H, Koike M, Tanaka C, et al. Tumor budding as a useful prognostic marker in T1-stage squamous cell carcinoma of the esophagus. J Surg Oncol 2013;108(1):42-6
   PubMed Web of Science ®Google Scholar
• Koike M, Kodera Y, Itoh Y, et al. Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor. Ann Surg Oncol 2008;15(7):1977-82
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Ohara M, Doumen H, et al. Correlation between tumor budding and post-resection prognosis in patients with invasive squamous cell carcinoma of the thoracic esophagus. World J Surg 2011;35(2):349-56
   PubMed Web of Science ®Google Scholar
• Roh MS, Lee JI, Choi PJ. Tumor budding as a useful prognostic marker in esophageal squamous cell carcinoma. Dis Esophagus 2004;17(4):333-7
   PubMed Web of Science ®Google Scholar
• Miyata H, Yoshioka A, Yamasaki M, et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer 2009;115(14):3324-34
   PubMed Web of Science ®Google Scholar
• Brown M, Sillah K, Griffiths EA, et al. Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers. Histopathology 2010;56(7):893-9
   PubMed Web of Science ®Google Scholar
• Pennathur A, Xi L, Litle VR, et al. Gene expression profiles in esophageal adenocarcinoma predict survival after resection. J Thorac Cardiovasc Surg 2013;145(2):505-12. discussion 512-3
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Hanyu N, Nakada K, et al. Profiling gene expression ratios of paired cancerous and normal tissue predicts relapse of esophageal squamous cell carcinoma. Cancer Res 2003;63(16):5159-64
   PubMed Web of Science ®Google Scholar
• Hammoud ZT, Badve S, Zhao Q, et al. Differential gene expression profiling of esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2009;137(4):829-34
   PubMed Web of Science ®Google Scholar
• Peters CJ, Rees JR, Hardwick RH, et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 2010;139(6):1995-2004; e15
   PubMed Web of Science ®Google Scholar
• Kim SM, Park YY, Park ES, et al. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 2010;5(11):e15074
   PubMedGoogle Scholar
• van Dekken H, Wink JC, Vissers KJ, et al. Genomic analysis of early adenocarcinoma of the esophagus or gastroesophageal junction: tumor progression is associated with alteration of 1q and 8p sequences. Genes Chromosomes Cancer 2006;45(5):516-25
   PubMed Web of Science ®Google Scholar
• Riegman PH, Vissers KJ, Alers JC, et al. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res 2001;61(7):3164-70
   PubMed Web of Science ®Google Scholar
• Doki Y, Shiozaki H, Tahara H, et al. Prognostic value of DNA ploidy in squamous cell carcinoma of esophagus. Analyzed with improved flow cytometric measurement. Cancer 1993;72(6):1813-18
   PubMed Web of Science ®Google Scholar
• Ishizuka T, Tanabe C, Sakamoto H, et al. Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH. Biochem Biophys Res Commun 2002;296(1):152-5
   PubMed Web of Science ®Google Scholar
• Metzger R, Schneider PM, Warnecke-Eberz U, et al. Molecular biology of esophageal cancer. Onkologie 2004;27(2):200-6
   PubMed Web of Science ®Google Scholar
• Ying J, Shan L, Li J, et al. Genome-wide screening for genetic alterations in esophageal cancer by aCGH identifies 11q13 amplification oncogenes associated with nodal metastasis. PLoS One 2012;7(6):e39797
   PubMedGoogle Scholar
• Rosenberg C, Geelen E, IJszenga MJ, et al. Spectrum of genetic changes in gastro-esophageal cancer cell lines determined by an integrated molecular cytogenetic approach. Cancer Genet Cytogenet 2002;135(1):35-41
   PubMed Web of Science ®Google Scholar
• Walch AK, Zitzelsberger HF, Bink K, et al. Molecular genetic changes in metastatic primary Barrett's adenocarcinoma and related lymph node metastases: comparison with nonmetastatic Barrett's adenocarcinoma. Mod Pathol 2000;13(7):814-24
   PubMed Web of Science ®Google Scholar
• Riegman PH, Vissers KJ, Alers JC, et al. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res 2001;61(7):3164-70
   PubMed Web of Science ®Google Scholar
• Pasello G, Agata S, Bonaldi L, et al. DNA copy number alterations correlate with survival of esophageal adenocarcinoma patients. Mod Pathol 2009;22(1):58-65
   PubMed Web of Science ®Google Scholar
• Rumiato E, Pasello G, Montagna M, et al. DNA copy number profile discriminates between esophageal adenocarcinoma and squamous cell carcinoma and represents an independent prognostic parameter in esophageal adenocarcinoma. Cancer Lett 2011;310(1):84-93
   PubMed Web of Science ®Google Scholar
• Brock MV, Gou M, Akiyama Y, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003;9(8):2912-19
   PubMed Web of Science ®Google Scholar
• Hoffmann AC, Vallböhmer D, Prenzel K, et al. Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol 2009;135(9):1231-7
   PubMed Web of Science ®Google Scholar
• Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92(22):1805-11
   PubMed Web of Science ®Google Scholar
• Zare M, Jazii FR, Alivand MR, et al. Qualitative analysis of Adenomatous Polyposis Coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker. BMC Cancer 2009;9:24
   PubMed Web of Science ®Google Scholar
• Jin Z, Olaru A, Yang J, et al. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res 2007;13(21):6293-300
   PubMed Web of Science ®Google Scholar
• Ling ZQ, Zhao Q, Zhou SL, et al. MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 2012;38(4):326-32
   PubMed Web of Science ®Google Scholar
• Jin Z, Mori Y, Yang J, et al. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene 2007;26(43):6332-40
   PubMed Web of Science ®Google Scholar
• Mandelker DL, Yamashita K, Tokumaru Y, et al. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005;65(11):4963-8
   PubMed Web of Science ®Google Scholar
• Hamilton JP, Sato F, Greenwald BD, et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol 2006;4(6):701-8
   PubMed Web of Science ®Google Scholar
• Goh XY, Rees JR, Paterson AL, et al. Integrative analysis of array-comparative genomic hybridization and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut 60:1317-26.2011
   PubMed Web of Science ®Google Scholar
• Ong CA, Shapiro J, Nason KS, et al. Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. J Clin Oncol 2013;31:1576-82
   PubMed Web of Science ®Google Scholar
• Kelly P, Paulin F, Lamont D, et al. Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer 2012;106(5):955-61
   PubMed Web of Science ®Google Scholar
• Komatsu S, Ichikawa D, Takeshita H, et al. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert Opin Biol Ther 2012;12(Suppl 1):S53-9
   PubMed Web of Science ®Google Scholar
• Kurashige J, Kamohara H, Watanabe M, et al. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol 2012;106(2):188-92
   PubMed Web of Science ®Google Scholar
• Ogawa R, Ishiguro H, Kuwabara Y, et al. Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med Mol Morphol 2009;42(2):102-9
   PubMed Web of Science ®Google Scholar
• Cai EH, Gao YX, Wei ZZ, et al. Serum miR-21 expression in human esophageal squamous cell carcinomas. Asian Pac J Cancer Prev 2012;13(4):1563-7
   PubMed Web of Science ®Google Scholar
• Akagi I, Miyashita M, Ishibashi O, et al. Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. Dis Esophagus 2011;24(7):523-30
   PubMed Web of Science ®Google Scholar
• Yokobori T, Suzuki S, Tanaka N, et al. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci 2013;104(1):48-54
   PubMed Web of Science ®Google Scholar
• Hummel R, Hussey DJ, Michael MZ, et al. MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma. J Gastrointest Surg 2011;15:429-38
   PubMed Web of Science ®Google Scholar
• Feber A, Xi L, Pennathur A, et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg 2011;91(5):1523-30
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97
   PubMed Web of Science ®Google Scholar
• Lubin JH, Cook MB, Pandeya N, et al. The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol 2012;36(3):306-16
   PubMed Web of Science ®Google Scholar
• Antonsson A, Nancarrow DJ, Brown IS, et al. High-risk human papillomavirus in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2010;19(8):2080-7
   PubMed Web of Science ®Google Scholar
• Chang F, Syrjänen S, Shen Q, et al. Evaluation of HPV, CMV, HSV and EBV in esophageal squamous cell carcinomas from a high-incidence area of China. Anticancer Res 2000;20(5C):3935-40
   PubMed Web of Science ®Google Scholar
• Oka M, Yamamoto K, Takahashi M, et al. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996;56(12):2776-80
   PubMed Web of Science ®Google Scholar
• Groblewska M, Mroczko B, et al. Interleukin 6 and C-reactive protein in esophageal cancer. Clin Chim Acta 2012;413(19-20):1583-90
   PubMed Web of Science ®Google Scholar
• Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al. Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 2008;46(3):359-64
   PubMed Web of Science ®Google Scholar
• Gockel I, Dirksen K, Messow CM, et al. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 2006;12(23):3746-50
   PubMed Web of Science ®Google Scholar
• Shimada H, Nabeya Y, Okazumi S, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003;83(4):248-52
   PubMed Web of Science ®Google Scholar
• Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001;182(2):197-201
   PubMed Web of Science ®Google Scholar
• Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005;18(3):146-50
   PubMed Web of Science ®Google Scholar
• Łukaszewicz-Zając M, Mroczko B, Kozłowski M, et al. Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. Dis Esophagus 2012;25(3):242-9
   PubMed Web of Science ®Google Scholar
• Zhao Y, Schetter AJ, Yang GB, et al. microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer 2013;132(12):2901-9
   PubMed Web of Science ®Google Scholar
• Wang MT, Chen G, An SJ, et al. Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinoma. Dis Esophagus 2012;25(7):664-70
   PubMed Web of Science ®Google Scholar
• Choy B, Bandla S, Xia Y, et al. Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma. BMC Gastroenterol 2012;12:146
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Yamai H, Seike J, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Ann Surg Oncol 2012;19(3):757-65
   PubMed Web of Science ®Google Scholar
• Ren HZ, Pan GQ, Wang JS, et al. Reduced stratifin expression can serve as an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Dig Dis Sci 2010;55(9):2552-60
   PubMed Web of Science ®Google Scholar
• Liu J, Fan H, Ma Y, et al. Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. PLoS One 2013;8(2):e56141
   PubMedGoogle Scholar
• Nishimori T, Tomonaga T, Matsushita K, et al. Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics 2006;6(3):1011-18
   PubMed Web of Science ®Google Scholar
• Ohtsuka M, Yamamoto H, Masuzawa T, et al. C4.4A Expression is associated with a poor prognosis of esophageal squamous cell carcinoma. Ann Surg Oncol 2013;20(8):2699-705
   PubMed Web of Science ®Google Scholar
• Madani K, Zhao R, Lim HJ, et al. Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study. Eur J Cardiothorac Surg 2010;37(6):1427-32
   PubMed Web of Science ®Google Scholar
• Wang Q, Ma C, Kemmner W. Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cell carcinoma. BMC Cancer 2013;13:137
   PubMedGoogle Scholar
• Kurashige J, Watanabe M, Iwatsuki M, et al. RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. Br J Cancer 2012;107(8):1233-8
   PubMed Web of Science ®Google Scholar
• Brabender J, Metzger R, Vallböhmer D, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer. Surgery 2012;151(2):306-12
   PubMed Web of Science ®Google Scholar
• Metzger R, Warnecke-Eberz U, Alakus H, et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg 2012;16(1):26-34; discussion 34
   PubMed Web of Science ®Google Scholar
• Metzger R, Heukamp L, Drebber U, et al. CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics 2010;11(8):1105-13
   PubMed Web of Science ®Google Scholar
• Hoffmann AC, Vallböhmer D, Prenzel K, et al. Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol 2009;135(9):1231-7
   PubMed Web of Science ®Google Scholar